Enzalutamide | List of Frontiers open access articles

Original Research

Published on 09 Jun 2025

ELOVL2 mediated stabilization of AR contributes to enzalutamide resistance in prostate cancer

in Cancer Cell Biology

Jinpeng Cen
Jiading Guo
Xianzi Zeng
Xianlu Song
Shengdong Ge
Mingkun Chen
Qianyi Li
Yuzhong Yu
Daojun Lv
Shanchao Zhao

Frontiers in Cell and Developmental Biology

doi 10.3389/fcell.2025.1598400

3,936 views
2 citations

Mini Review

Published on 24 May 2018

Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer

in Cancer Molecular Targets and Therapeutics

Alexandra Vander Ark
Jingchen Cao
Xiaohong Li

Frontiers in Oncology

doi 10.3389/fonc.2018.00180

17,371 views
48 citations

Case Report

Published on 17 Nov 2021

Stevens-Johnson Syndrome Caused by Enzalutamide: A Case Report and Literature Review

in Pharmacology of Anti-Cancer Drugs

Min Deng
Huirong Chai
Meng Yang
Xueman Wei
Wenjun Zhang
Xuebin Wang
Juanjuan Li
Zhuo Wang
Haitao Chen

Frontiers in Oncology

doi 10.3389/fonc.2021.736975

5,396 views
9 citations

Original Research

Published on 07 Mar 2022

Comparative Effectiveness of Abiraterone and Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer in Taiwan

in Genitourinary Oncology

Pei-Yu Li
Ying-Hao Lu
Chung-Yu Chen

Frontiers in Oncology

doi 10.3389/fonc.2022.822375

11,612 views
10 citations

Original Research

Published on 14 Jul 2022

Phase II Study of ENZAlutamide Combined With Hypofractionated Radiation Therapy (ENZART) for Localized Intermediate Risk Prostate Cancer

in Radiation Oncology

Pedro C. Lara
Juan I. Rodríguez-Melcón
Amalia Palacios-Eito
Antonio Lozano
Asunción Hervás-Morón
Elena Villafranca
Alfonso Gómez-Iturriaga
Gemma Sancho
Xavier Maldonado

Frontiers in Oncology

doi 10.3389/fonc.2022.891886

6,244 views
6 citations

Original Research

Published on 21 Jul 2021

Abiraterone In Vitro Is Superior to Enzalutamide in Response to Ionizing Radiation

in Genitourinary Oncology

Timothy C. Wright
Victoria L. Dunne
Ali H. D. Alshehri
Kelly M. Redmond
Aidan J. Cole
Kevin M. Prise

Frontiers in Oncology

doi 10.3389/fonc.2021.700543

7,629 views
9 citations

Systematic Review

Published on 27 Aug 2021

Efficacy and Safety of Abiraterone Acetate and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis

in Genitourinary Oncology

ZhenHeng Wei
ChuXin Chen
BoWen Li
YongYue Li
Hong Gu

Frontiers in Oncology

doi 10.3389/fonc.2021.732599

13,020 views
16 citations

Original Research

Published on 18 Jun 2021

Real-World Data on Outcomes in Metastatic Castrate-Resistant Prostate Cancer Patients Treated With Abiraterone or Enzalutamide: A Regional Experience

in Genitourinary Oncology

Rachel Raju
Arvind Sahu
Myron Klevansky
Javier Torres

Frontiers in Oncology

doi 10.3389/fonc.2021.656146

8,267 views
12 citations

Original Research

Published on 21 May 2021

Androgen Receptor, Although Not a Specific Marker For, Is a Novel Target to Suppress Glioma Stem Cells as a Therapeutic Strategy for Glioblastoma

in Cancer Molecular Targets and Therapeutics

Nan Zhao
Fei Wang
Shaheen Ahmed
Kan Liu
Chi Zhang
Sahara J. Cathcart
Dominick J. DiMaio
Michael Punsoni
Bingjie Guan
Ping Zhou

Frontiers in Oncology

doi 10.3389/fonc.2021.616625

11,082 views
77 citations

Original Research

Published on 18 May 2021

Treatment-Emergent Co-Morbidities and Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide

in Drugs Outcomes Research and Policies

Yi-Ting Lin
Yen-Chun Huang
Chih-Kuan Liu
Tian-Shyug Lee
Mingchih Chen
Yu-Ning Chien

Frontiers in Pharmacology

doi 10.3389/fphar.2021.669236

5,975 views
9 citations

Systematic Review

Published on 18 Sep 2020

Comparison of Current Systemic Combination Therapies for Metastatic Hormone-Sensitive Prostate Cancer and Selection of Candidates for Optimal Treatment: A Systematic Review and Bayesian Network Meta-Analysis

in Genitourinary Oncology

Junru Chen
Yuchao Ni
Guangxi Sun
Banghua Liao
Xingming Zhang
Jinge Zhao
Sha Zhu
Zhipeng Wang
Pengfei Shen
Hao Zeng

Frontiers in Oncology

doi 10.3389/fonc.2020.519388

12,355 views
25 citations

Original Research

Published on 19 May 2022

Pharmacist-Urologist Collaborative Management Improves Clinical Outcomes in Patients With Castration-Resistant Prostate Cancer Receiving Enzalutamide

in Drugs Outcomes Research and Policies

Masaki Hirabatake
Hiroaki Ikesue
Yuna Iwama
Kei Irie
Shintaro Yoshino
Toshinari Yamasaki
Tohru Hashida
Mutsushi Kawakita
Nobuyuki Muroi

Frontiers in Pharmacology

doi 10.3389/fphar.2022.901099

4,877 views
9 citations

Review

Published on 09 Mar 2023

Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis

in Cancer Endocrinology

Xiangyu Chen
Qihua Wang
Yang Pan
Shangren Wang
Yuezheng Li
Hao Zhang
Mingming Xu
Hang Zhou
Xiaoqiang Liu

Frontiers in Endocrinology

doi 10.3389/fendo.2023.1134719

12,623 views
5 citations

Original Research

Published on 15 Nov 2021

The circRAB3IP Mediated by eIF4A3 and LEF1 Contributes to Enzalutamide Resistance in Prostate Cancer by Targeting miR-133a-3p/miR-133b/SGK1 Pathway

in Molecular and Cellular Oncology

Dong Chen
Yaqin Wang
Feiya Yang
Adili Keranmu
Qingxin Zhao
Liyuan Wu
Sujun Han
Nianzeng Xing

Frontiers in Oncology

doi 10.3389/fonc.2021.752573

4,566 views
11 citations

Review

Published on 25 Nov 2024

Long noncoding RNA mediates enzalutamide resistance and transformation in neuroendocrine prostate cancer

in Pharmacology of Anti-Cancer Drugs

Zhe Zhu
Wenjing Xuan
Chaohui Wang
Chancan Li

Frontiers in Oncology

doi 10.3389/fonc.2024.1481777

3,471 views
1 citation

Systematic Review

Published on 29 Aug 2025

Comparing the safety and efficacy of systemic therapies for high-risk biochemically recurrent hormone-sensitive prostate cancer: a network meta-analysis

in Genitourinary Oncology

Armen Aprikian
Andrew Chilelli
Thomas McLean
Anchen Nasr
Arijit Ganguli
Alexis Serikoff
Franco Guzman
Ifigeneia Barouma
Maria Zacharioudaki
Stephen J. Freedland

Frontiers in Oncology

doi 10.3389/fonc.2025.1638405

4,803 views

Articles

ELOVL2 mediated stabilization of AR contributes to enzalutamide resistance in prostate cancer

Mechanisms and Approaches for Overcoming Enzalutamide Resistance in Prostate Cancer

Stevens-Johnson Syndrome Caused by Enzalutamide: A Case Report and Literature Review

Comparative Effectiveness of Abiraterone and Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer in Taiwan

Phase II Study of ENZAlutamide Combined With Hypofractionated Radiation Therapy (ENZART) for Localized Intermediate Risk Prostate Cancer

Abiraterone In Vitro Is Superior to Enzalutamide in Response to Ionizing Radiation

Efficacy and Safety of Abiraterone Acetate and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis

Real-World Data on Outcomes in Metastatic Castrate-Resistant Prostate Cancer Patients Treated With Abiraterone or Enzalutamide: A Regional Experience

Androgen Receptor, Although Not a Specific Marker For, Is a Novel Target to Suppress Glioma Stem Cells as a Therapeutic Strategy for Glioblastoma

Treatment-Emergent Co-Morbidities and Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide

Comparison of Current Systemic Combination Therapies for Metastatic Hormone-Sensitive Prostate Cancer and Selection of Candidates for Optimal Treatment: A Systematic Review and Bayesian Network Meta-Analysis

Pharmacist-Urologist Collaborative Management Improves Clinical Outcomes in Patients With Castration-Resistant Prostate Cancer Receiving Enzalutamide

Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis

The circRAB3IP Mediated by eIF4A3 and LEF1 Contributes to Enzalutamide Resistance in Prostate Cancer by Targeting miR-133a-3p/miR-133b/SGK1 Pathway

Long noncoding RNA mediates enzalutamide resistance and transformation in neuroendocrine prostate cancer

Comparing the safety and efficacy of systemic therapies for high-risk biochemically recurrent hormone-sensitive prostate cancer: a network meta-analysis